This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 May 1;19(9):2578; author reply 2580-2.

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

M S Copur, P Ledakis, M Bolton, M Norvell, J Muhvic

PMID: 11331343

Comment

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?

M S Copur et al. J Clin Oncol. 2001.

. 2001 May 1;19(9):2578; author reply 2580-2.

Authors

M S Copur, P Ledakis, M Bolton, M Norvell, J Muhvic

PMID: 11331343

No abstract available

PubMed Disclaimer

Comment on

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Bonneterre J, et al. J Clin Oncol. 2000 Nov 15;18(22):3748-57. doi: 10.1200/JCO.2000.18.22.3748. J Clin Oncol. 2000. PMID: 11078487 Clinical Trial.
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Nabholtz JM, et al. J Clin Oncol. 2000 Nov 15;18(22):3758-67. doi: 10.1200/JCO.2000.18.22.3758. J Clin Oncol. 2000. PMID: 11078488 Clinical Trial.

Similar articles

Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Costa SD, Kaufmann M. Costa SD, et al. J Clin Oncol. 2001 May 1;19(9):2580; author reply 2580-2. doi: 10.1200/JCO.2001.19.9.2580. J Clin Oncol. 2001. PMID: 11331346 No abstract available.
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Tonkin K. Tonkin K. J Clin Oncol. 2001 May 1;19(9):2579-80; author reply 2580-2. doi: 10.1200/JCO.2001.19.9.2579. J Clin Oncol. 2001. PMID: 11331344 No abstract available.
Is anastrozole superior to tamoxifen as first-line therapy for advanced breast cancer?
Bagley CM Jr, Rowbotham RK. Bagley CM Jr, et al. J Clin Oncol. 2001 May 1;19(9):2578-9; author reply 2580-2. doi: 10.1200/JCO.2001.19.9.2578. J Clin Oncol. 2001. PMID: 11331342 No abstract available.
Changes in endocrine therapy: anastrozole and advanced breast cancer in postmenopausal women.
Nabholtz JM. Nabholtz JM. Am J Hosp Palliat Care. 2004 Nov-Dec;21(6):457-65. doi: 10.1177/104990910402100612. Am J Hosp Palliat Care. 2004. PMID: 15612238 Review.
Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
Nabholtz JM. Nabholtz JM. Oncology. 2006;70(1):1-12. doi: 10.1159/000091180. Epub 2006 Jan 26. Oncology. 2006. PMID: 16439860 Review.

See all similar articles

Cited by

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials.
Ferretti G, Bria E, Giannarelli D, Felici A, Papaldo P, Fabi A, Di Cosimo S, Ruggeri EM, Milella M, Ciccarese M, Cecere FL, Gelibter A, Nuzzo C, Cognetti F, Terzoli E, Carlini P. Ferretti G, et al. Br J Cancer. 2006 Jun 19;94(12):1789-96. doi: 10.1038/sj.bjc.6603194. Epub 2006 May 30. Br J Cancer. 2006. PMID: 16736002 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information